Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact of lipid-lowering agents in this population.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Hypolipidemic Agents

Criteria

Inclusion Criteria:

• fullfill all criteria of Bohan and Peter (1975)

• dyslipidemia

• age> 18 years

• prednisone ≤ 0.25 mg/kg/day (or ≤ 15mg/ ay) in the last three months

• without changing nutritional habits in the last three months, and during the study period

• no change of lifestyle in the last three months, and during the study period

Exclusion Criteria:

Patients with:

• disease relapsing

• overlapping myositis

• neoplasia associated myositis

• diabetes mellitus

• current and/or chronic infections

• patients undergoing major surgery within six months prior to the study

• pregnant patients

• previous use of lipid-lowering agents in the last 6 months

• in the use of cyclosporin, erythromycin, clarithromycin, fibrates, niacin, azole antifungals, cimetidine, diltiazem

• active liver disease or persistent elevations of hepatic enzymes, with no apparent cause, exceeding three times the upper limit of normality